Who
Eliyahu Sharon Kalif
EVP, Chief Financial Officer
Company insider
Files Form 4 as: EVP, Chief Financial Officer, Teva Pharmaceutical Industries.
In numbers
- Trades disclosed
- 85
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $45.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 13 Feb 2020
- Last trade
- 11 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 16 Jun 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $3.6M106,563 at $34.10 | filing |
| 11 Jun 2026filed 16 Jun 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $3.6M106,563 at $34.10 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $5.5M153,251 at $35.61 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $5.5M153,251 at $35.61 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —19,916 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —19,916 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —19,916 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —19,916 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —33,512 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —23,251 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —33,512 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —33,512 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —23,251 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —53,175 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —23,251 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —53,175 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —33,512 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —23,251 | filing |
| 3 Mar 2026filed 5 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —49,800 | filing |
| 3 Mar 2026filed 5 Mar 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —141,478 | filing |
News
Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 16 Oct 2026Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $50.00TEVA · dailypolitical.com · 15 Oct 2026Analyzing Astrazeneca (NYSE:AZN) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Eliyahu Sharon Kalif; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.